No abstract

No abstract

No abstract

PurposeTo consider the extent to which the concept of social enterprise fits within facilities management (FM) thinking in helping to create community benefit in the process of delivering housing market renewal (HMR) in the UK. HMR via its HMR pathfinder organisations is part of many strategies in the ODPM (2003), introduced by the UK government to tackle low demand and housing abandonment across the UK.Design/methodology/approachThis paper considers two key themes. First, it focuses on social enterprise practice within the context of supporting and sustaining the existing economy of the local communities in the most deprived areas in the UK. Second, it discusses the present understanding of FM practices and how far these fit within social enterprise practices in delivering social objectives.FindingsSocial enterprises tackle a wide range of social, environmental and economic issues to achieve public benefit. It is a promising vehicle for the development of community‐based FM.Originality/valueThe paper builds on established literature and generates debate on the role of FM within the context of relevant organisations that offers new ways of operating for public benefit rather than purely maximising profits for shareholders.

Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventative therapy to maintain healthspan. Thus far, however, there is limited data available on side effects or efficacy associated with use of rapamycin in this context. To begin to address this gap in knowledge, we collected data from 333 adults with a history of off-label use of rapamycin by survey. Similar data were also collected from 172 adults who had never used rapamycin. Here, we describe the general characteristics of a patient cohort using off-label rapamycin and present initial evidence that rapamycin can be used safely in adults of normal health status. Supplementary Information The online version contains supplementary material available at 10.1007/s11357-023-00818-1.